[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100463793":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":93,"collaborators":19,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":19,"enrollmentInfo":105,"targetDuration":19,"studyType":108,"phases":109,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":23,"whyStopped":19,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Lyell Immunopharma, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LYL273","EXPERIMENTAL","Single infusion of LYL273 at the dose assigned to an individual participant.\n\nAll participants will receive the same investigational therapy with the dose administered dependent upon the dose level they are assigned to in a sequential manner.",[13],"Drug: LYL273",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)",[9],null,[21,45,59,78],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"City of Hope Comprehensive Cancer Center","RECRUITING","Duarte","California","91010","United States","US",{"type":30,"coordinates":31},"Point",[32,33],-117.97729,34.13945,{"lat":33,"lon":32},[36,41],{"name":37,"role":38,"phone":39,"phoneExt":19,"email":40},"Jessica Mathias","CONTACT","626-218-4088","jmathias@coh.org",{"name":42,"role":38,"phone":43,"phoneExt":19,"email":44},"Kimberly Le","626-218-2997","kimle@coh.org",{"facility":46,"status":23,"city":47,"state":25,"zip":48,"country":27,"countryCode":28,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"University of California San Francisco Medical Center","San Francisco","94143",{"type":30,"coordinates":50},[51,52],-122.41942,37.77493,{"lat":52,"lon":51},[55],{"name":56,"role":38,"phone":57,"phoneExt":19,"email":58},"UCSF Team","415-818-4579","HDFCCC.CIP@ucsf.edu",{"facility":60,"status":23,"city":61,"state":62,"zip":63,"country":27,"countryCode":28,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"University of Colorado Hospital - Anschutz Cancer Pavilion","Aurora","Colorado","80045",{"type":30,"coordinates":65},[66,67],-104.83192,39.72943,{"lat":67,"lon":66},[70,74],{"name":71,"role":38,"phone":72,"phoneExt":19,"email":73},"Meredith Waring","303-724-9840","meredith.waring@cuanschutz.edu",{"name":75,"role":38,"phone":76,"phoneExt":19,"email":77},"Alexander Pung","303-724-9632","alexander.pung@cuanschutz.edu",{"facility":79,"status":23,"city":80,"state":81,"zip":82,"country":27,"countryCode":28,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215-5418",{"type":30,"coordinates":84},[85,86],-71.05977,42.35843,{"lat":86,"lon":85},[89],{"name":90,"role":38,"phone":91,"phoneExt":19,"email":92},"Jamie Dela Cruz","857-215-2833","jamiep_delacruz@dfci.harvard.edu",{"type":94,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100463793","phase-1-lyl273-for-patients-with-relapsed-or-refractory-mcrc-100463793",false,"NCT05319314","LYL273 for Patients With Relapsed or Refractory mCRC","A Phase 1\u002F2 Multicenter Study Evaluating the Safety and Efficacy of LYL273 in Patients With Relapsed or Refractory Metastatic Colorectal Cancer","CARABiNER","Inclusion Criteria:\n\n* Adults \\> 18 years old\n* Clinical and histopathological diagnosis of relapsed or refractory metastatic colorectal cancer\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Limited liver disease (less than 7 lesions with largest lesion less than 3 cm)\n* No surgical options with curative intent\n* Received prior therapy with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy in the advanced or metastatic setting, an anti-vascular endothelial growth factor (anti-VEGF) biological therapy if not contraindicated, and if RAS wild-type an anti-epidermal growth factor receptor (anti-EGFR) therapy in a manner consistent with National Comprehensive Cancer Network (NCCN) guidelines. Treatment must have been discontinued for disease progression or intolerance to therapy\n* Have at least one extracranial measurable target lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 standard\n\nExclusion Criteria:\n\n* Participants with tumor lesion(s) in a location that may cause perforation of an organ or structure (such as the digestive tract, urinary bladder, or blood vessel) with LYL273 therapy\n* Active central nervous system (CNS) involvement by malignancy on magnetic resonance imaging (MRI) or contrast-enhanced computed tomography (CT)\n* History of or active viral infection including human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)\n* History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome, or any autoimmune disease with CNS involvement in the 2-year period leading up to the study enrollment\n* No active infectious diseases or comorbid conditions that would interfere with safety or data quality\n* Pregnant or breast-feeding women\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply","ALL","18 Years",{"count":106,"type":107},155,"ESTIMATED","INTERVENTIONAL",[110,111],"PHASE1","PHASE2","This is a Phase 1\u002F2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.",[114],"Colorectal Cancer",[116,117,118,119,120,121,122,123,124,125,126],"relapsed metastatic colorectal cancer","refractory metastatic colorectal cancer","chimeric antigen receptors (CAR)","colorectal cancer","metastatic colorectal cancer","mCRC","CAR T-cell","guanylyl cyclase C","GCC","colorectal neoplasms","autologous T cells","2026-06-05",{"date":129,"type":130},"2026-06-09","ACTUAL",{"date":132,"type":130},"2022-08-01",{"date":134,"type":107},"2032-06",{"name":5,"class":6},4]